Osmotica Pharmaceuticals (NASDAQ:OSMT) posted its earnings results on Thursday. The company reported ($2.15) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($1.85), Fidelity Earnings reports. The business had revenue of $65.46 million during the quarter, compared to analyst estimates of $49.13 million. Osmotica Pharmaceuticals had a negative net margin of 97.91% and a negative return on equity of 32.14%.
Shares of Osmotica Pharmaceuticals stock traded up $0.10 on Friday, reaching $4.12. The stock had a trading volume of 153,500 shares, compared to its average volume of 95,511. The business’s 50-day moving average price is $4.18 and its two-hundred day moving average price is $3.46. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.49 and a current ratio of 1.78. Osmotica Pharmaceuticals has a fifty-two week low of $2.20 and a fifty-two week high of $9.75. The stock has a market cap of $205.05 million and a P/E ratio of -8.08.
OSMT has been the subject of a number of analyst reports. ValuEngine cut shares of Osmotica Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 1st. Zacks Investment Research cut shares of Osmotica Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, September 7th. Wells Fargo & Co restated a “buy” rating on shares of Osmotica Pharmaceuticals in a research note on Friday, August 9th. Finally, Jefferies Financial Group set a $10.00 price objective on shares of Osmotica Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Osmotica Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $11.67.
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.
Featured Story: Fibonacci Channel
Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.